To hear about similar clinical trials, please enter your email below

Trial Title: Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

NCT ID: NCT06496256

Condition: Prostate Cancer

Conditions: Official terms:
Prostatic Neoplasms

Study type: Interventional

Study phase: N/A

Overall status: Not yet recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Intervention model description: Prospective, randomized, controlled, single-blinded multicenter study

Primary purpose: Prevention

Masking: Single (Participant)

Masking description: All subjects who sign a consent and meet inclusion and exclusion criteria will be randomized to the treatment or the control arm.

Intervention:

Intervention type: Device
Intervention name: Barrigel
Description: Barrigel is an absorbable gel based on Non-Animal Stabilized Hyaluronic Acid (NASHA™) that is injected into the peri-rectal space
Arm group label: Treatment Arms

Intervention type: Device
Intervention name: Transrectal Ultrasound
Description: All subjects will have a transrectal ultrasound (TRUS) conducted. In the control subjects this will act as a sham procedure. For the investigational subjects, the TRUS will be used to visualize the placement of the needle
Arm group label: Control Arm
Arm group label: Treatment Arms

Summary: Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.

Detailed description: Barrigel is composed of biodegradable material and maintains space for the entire course of prostate or prostate bed radiotherapy and is intended to be absorbed by the patient's body over time. To evaluate the safety and effectiveness of Barrigel to reduce the radiation dose delivered to the anterior rectum by creating a space when injected between the rectum and the prostate bed in men receiving definitive external beam radiation therapy (intensity-modulated radiation therapy) for recurrence of prostate cancer after radical prostatectomy. A prospective, randomized, controlled, single-masked multicenter study.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 3. Prostatectomy surgeon notes specifying successful bilateral nerve Sparing procedure 4. Documentation of an intra or interfascial radical prostatectomy 5. Confirmed diagnosis of adenocarcinoma of the prostate treated primarily with radical prostatectomy with pN0 or pNX pathologic stage 6. No radiographic evidence of local, regional, or distant metastatic disease via PSMA PET or Axumin fluciclovine F18 scan 7. Prostate specific antigen (PSA) 0.1 ng/mL or higher 8. Intent to receive definitive radiation therapy to the prostate bed 9. Written informed consent for study participation prior to study enrollment Exclusion Criteria: 1. Known allergy to hyaluronic acid 2. Pathologic T4 disease 3. Prior local prostate cancer therapy including cryotherapy or brachytherapy. 4. Prior post-prostatectomy or pelvic radiation therapy 5. Planned elective pelvic lymph node radiation therapy 6. Prior anorectal surgery (e.g. low anterior resection, abdominoperineal resection, absence of a rectum) 7. Inflammatory bowel disease requiring treatment with steroids (e.g. Crohn's disease, ulcerative colitis) 8. Active connective tissue disorder including lupus or scleroderma 9. Any urogenital abnormality that could limit the ability to access the Barrigel injection site 10. White blood cell count <4000/uL or >12,000/uL. 11. Hemoglobin <10 g/dL (transfusion or other intervention to achieve this is acceptable). 12. Active bleeding disorder or clinically significant coagulopathy defined as PTT >35 seconds or INR >1.4 or platelet count <100,000/mm3. 13. Serum AST/ALT >2.5 times the institutional upper limit of normal 14. Creatinine >2.0 mg/dL 15. Bilirubin >2.0 mg/dL 16. History of chronic renal failure. 17. History of uncontrolled diabetes (e.g. symptomatic hyperglycemia that is not controlled with medical management; fasting blood glucose >300 mg/dL). 18. History of acquired immunodeficiency syndrome (AIDS). Patients with controlled HIV infection (CD4+ T-cell counts ≥ 350 cells/µL) and no history of AIDS-defining opportunistic infections may be included. 19. Contraindication to having an MRI or PSMA/PET scan (e.g. non-MRI compatible device). 20. Presence of bilateral hip implants, although unilateral hip implant may be permissible if the implant is MRI compatible and does not produce artifact that interferes with any requirements of the study protocol 21. Subject unable or unwilling to comply with study requirements 22. Any condition that in the investigator's opinion would prevent administration or completion of study therapy

Gender: Male

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: GenesisCare Ringwood

Address:
City: Melbourne
Zip: 3002
Country: Australia

Start date: August 5, 2024

Completion date: December 31, 2027

Lead sponsor:
Agency: Palette Life Sciences, Inc.
Agency class: Industry

Collaborator:
Agency: Teleflex
Agency class: Industry

Source: Palette Life Sciences, Inc.

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06496256

Login to your account

Did you forget your password?